Meichen Li

发表

Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis.

Jing Chen, Likun Chen, X. Hou, 2022, Future oncology.

Comparing organ‐specific immune‐related adverse events for immune checkpoint inhibitors: A Bayesian network meta‐analysis

Likun Chen, X. Hou, Meichen Li, 2021, Clinical and translational medicine.

Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)

Likun Chen, Q. Ou, X. Hou, 2022, BMC Medicine.

Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors.

Likun Chen, X. Hou, Zicheng Yu, 2022, American journal of cancer research.

Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)

Jing Chen, Likun Chen, K. Sai, 2022, Oncoimmunology.

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases

W. Feng, Honghua H. Jiang, Likun Chen, 2023, JAMA network open.

Management of Non-Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study.

Likun Chen, K. Sai, X. Hou, 2020, Clinical lung cancer.

Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial.

Likun Chen, Lie Zheng, X. Hou, 2023, Lung cancer.

Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)

Likun Chen, Q. Ou, X. Hou, 2022, BMC Medicine.

Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

W. Feng, Likun Chen, X. Hou, 2020, Frontiers in Oncology.

Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Xinke Zhang, A. Gari, Meichen Li, 2022, Journal of Translational Medicine.

Gefitinib Plus Chemotherapy Versus Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer Patients with Brain Metastases (GAP BRAIN): An Open-Label, Randomized, Multicenter, Phase 3 Study

W. Feng, Honghua H. Jiang, Jing Chen, 2022, SSRN Electronic Journal.

ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061).

Likun Chen, X. Hou, Hongyu Han, 2022, Lung cancer.

Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases

Meichen Li, Baishen Zhang, Jing Chen, 2023, Oncoimmunology.

Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Meichen Li, Baishen Zhang, Jing Chen, 2024, Journal of inflammation research.